Sirna Therapeutics, a wholly owned subsidiary of Merck and Co., 1700 Owens St, 4th Floor, San Francisco, CA 94158, USA.
Nucleic Acids Res. 2010 Jan;38(2):660-71. doi: 10.1093/nar/gkp913. Epub 2009 Nov 16.
Small interfering RNAs (siRNAs) are short, double-stranded RNAs that use the endogenous RNAi pathway to mediate gene silencing. Phosphorylation facilitates loading of a siRNA into the Ago2 complex and subsequent cleavage of the target mRNA. In this study, 2', 3' seco nucleoside modifications, which contain an acylic ribose ring and are commonly called unlocked nucleic acids (UNAs), were evaluated at all positions along the guide strand of a siRNA targeting apolipoprotein B (ApoB). UNA modifications at positions 1, 2 and 3 were detrimental to siRNA activity. UNAs at positions 1 and 2 prevented phosphorylation by Clp1 kinase, abrogated binding to Ago2, and impaired Ago2-mediated cleavage of the mRNA target. The addition of a 5'-terminal phosphate to siRNA containing a position 1 UNA restored ApoB mRNA silencing, Ago2 binding, and Ago2 mediated cleavage activity. Position 1 UNA modified siRNA containing a 5'-terminal phosphate exhibited a partial restoration of siRNA silencing activity in vivo. These data reveal the complexity of interpreting the effects of chemical modification on siRNA activity, and exemplify the importance of using multiple biochemical, cell-based and in vivo assays to rationally design chemically modified siRNA destined for therapeutic use.
小干扰 RNA(siRNA)是短的双链 RNA,利用内源性 RNAi 途径介导基因沉默。磷酸化有助于将 siRNA 加载到 Ago2 复合物中,并随后切割靶 mRNA。在这项研究中,2'、3' 位非环核苷修饰物(含有非环核糖环,通常称为非锁核酸(UNA))在靶向载脂蛋白 B(ApoB)的 siRNA 的引导链上的所有位置进行了评估。在位置 1、2 和 3 的 UNA 修饰对 siRNA 活性有害。位置 1 和 2 的 UNAs 阻止了 Clp1 激酶的磷酸化,破坏了与 Ago2 的结合,并损害了 Ago2 介导的 mRNA 靶标切割。在含有位置 1 UNA 的 siRNA 中添加 5'-末端磷酸基团恢复了 ApoB mRNA 沉默、Ago2 结合和 Ago2 介导的切割活性。含有 5'-末端磷酸基团的位置 1 UNA 修饰的 siRNA 在体内显示出部分恢复 siRNA 沉默活性。这些数据揭示了解释化学修饰对 siRNA 活性影响的复杂性,并说明了使用多种生化、基于细胞和体内测定来合理设计用于治疗用途的化学修饰 siRNA 的重要性。